eEdition Subscribe Log in
Tuesday, April 16, 2024
41.0°F
This Oct. 7, 2003 file photo shows a closeup of a human brain affected by Alzheimer's disease, on display at the Museum of Neuroanatomy at the University at Buffalo in Buffalo, N.Y. On Friday, Jan. 6, 2023, U.S. health officials approved Leqembi, a new Alzheimer’s drug that modestly slows the brain-robbing disease. The Food and Drug Administration granted the approval Friday for patients in the early stages of Alzheimer's. (AP Photo/David Duprey)

This Oct. 7, 2003 file photo shows a closeup of a human brain affected by Alzheimer's disease, on display at the Museum of Neuroanatomy at the University at Buffalo in Buffalo, N.Y. On Friday, Jan. 6, 2023, U.S. health officials approved Leqembi, a new Alzheimer’s drug that modestly slows the brain-robbing disease. The Food and Drug Administration granted the approval Friday for patients in the early stages of Alzheimer's. (AP Photo/David Duprey)

January 6, 2023

Stories this photo appears in:

Alzheimer's drug that modestly slows disease OK'd by FDA
January 6, 2023 11:25 a.m.

Alzheimer's drug that modestly slows disease OK'd by FDA

Some 6 million people in the U.S. and many more worldwide have Alzheimer’s